Cyanosafracin B

CAS No. 96996-50-8

Cyanosafracin B ( CBR28-1; Cyanoquinonamine )

Catalog No. M25019 CAS No. 96996-50-8

Cyanosafracin B is a compound which can be used in the synthesis of ecteinascidin ET-743 (an antitumor chemotherapy drug).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 155 In Stock
10MG 245 In Stock
25MG 484 In Stock
50MG 700 In Stock
100MG 981 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cyanosafracin B
  • Note
    Research use only, not for human use.
  • Brief Description
    Cyanosafracin B is a compound which can be used in the synthesis of ecteinascidin ET-743 (an antitumor chemotherapy drug).
  • Description
    Cyanosafracin B is a compound which can be used in the synthesis of ecteinascidin ET-743 (an antitumor chemotherapy drug).
  • Synonyms
    CBR28-1; Cyanoquinonamine
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    96996-50-8
  • Formula Weight
    549.6
  • Molecular Formula
    C29H35N5O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@H](N)C(NC[C@H]1C2=C(C(C(C)=C(OC)C2=O)=O)C[C@@]3([H])[C@@]4([H])C5=C(O)C(OC)=C(C)C=C5C[C@@](N4C)([H])[C@H](C#N)N31)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • PALATINOSE

    PALATINOSE is a natural occurring disaccharide composed of alpha-1,6-linked glucose and fructose, synergetic inhibitory effect on lung metastasis of LA795 xenograft tumor.

  • MDL-28170

    Calpain Inhibitor III is a potent, cell-permeable inhibitor of calpain I and II (Ki = 8 nM)., The Calpain Inhibitor III, also referenced under CAS 88191-84-8, controls the biological activity of Calpain.

  • LDC7559

    LDC7559 inhibits gasdermin D (GSDMD) by blocking neutrophil extracellular trap (NET) at late stage.